Mahdi Habibi-Anbouhi

Mahdi Habibi-Anbouhi

Auto-generated profile, based on publicly available information

Mahdi Habibi-Anbouhi

National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in Molecular Immunology
Verified
Journal Article
Closed access
MBMahdi Behdani
Mahdi Behdani
SZSirous Zeinali
Sirous Zeinali
HKHossein Khanahmad
Hossein Khanahmad
MKMorteza Karimipour
Morteza Karimipour
NANader Asadzadeh
Nader Asadzadeh
Serge MuyldermansSerge Muyldermans
Serge Muyldermans

1 January 2013 in New Biotechnology
Verified
Journal Article
Closed access
MBMahdi Behdani
Mahdi Behdani
SZSirous Zeinali
Sirous Zeinali
MKMorteza Karimipour
Morteza Karimipour
HKHossein Khanahmad
Hossein Khanahmad
SSSteve Schoonooghe
Steve Schoonooghe
Serge MuyldermansSerge Muyldermans
Serge Muyldermans

1 May 2015 in Molecular Immunology
Verified
Journal Article
Closed access
FKFatemeh Kazemi-Lomedasht
Fatemeh Kazemi-Lomedasht
MBMahdi Behdani
Mahdi Behdani
Kamran Pooshang BagheriKamran Pooshang Bagheri
Kamran Pooshang Bagheri
MHMahdi Habibi-Anbouhi
Mahdi Habibi-Anbouhi
MAMohsen Abolhassani
Mohsen Abolhassani
HMHasan Mirzahoseini
Hasan Mirzahoseini

4 July 2023 in Biomarker Research
Verified
Journal Article
Open access
PDF file
HDHamed Dabiri
Hamed Dabiri
PKPooria Safarzadeh Kozani
Pooria Safarzadeh Kozani
MAMahdi Habibi Anbouhi
Mahdi Habibi Anbouhi
MGMohadeseh Mirzaee Godarzee
Mohadeseh Mirzaee Godarzee
MHMohammad Hossein Haddadi
Mohammad Hossein Haddadi
ESEnsiyeh Hajizadeh Saffar
Ensiyeh Hajizadeh Saffar
Chimeric antigen receptor (CAR) T cells and natural killer (NK) cells are genetically engineered immune cells that can detect target antigens on the surface of target cells and eliminate them following adoptive transfer. Recent progress in CAR-based therapies has led to outstanding clinical success in certain patients with leukemias and lymphomas and offered therapeutic benefits to those resistant to conventional therapies. The universal approach to stable CAR transgene delivery into the T/NK cells is the use of viral particles. Such approaches mediate semi-random transgene insertions spanning the entire genome with a high preference for integration into sites surrounding highly-expressed genes and active loci. Regardless of the variable CAR expression level based on the integration site of the CAR transgene, foreign integrated DNA fragments may affect the neighboring endogenous genes and chromatin structure and potentially change a transduced T/NK cell behavior and function or even favor cellular transformation. In contrast, site-specific integration of CAR constructs using recent genome-editing technologies could overcome the limitations and disadvantages of universal random gene integration. Herein, we explain random and site-specific integration of CAR transgenes in CAR-T/NK cell therapies. Also, we tend to summarize the methods for site-specific integration as well as the clinical outcomes of certain gene disruptions or enhancements due to CAR transgene integration. Also, the advantages and limitations of using site-specific integration methods are discussed in this review. Ultimately, we will introduce the genomic safe harbor (GSH) standards and suggest some appropriate safety prospects for CAR integration in CAR-T/NK cell therapies.

30 March 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EHE. Hajizadeh-Saffar
E. Hajizadeh-Saffar
YTYaser Tahamtani
Yaser Tahamtani
NAN. Aghdami
N. Aghdami
KAK. Azadmanesh
K. Azadmanesh
MHM. Habibi-Anbouhi
M. Habibi-Anbouhi
HBHossein Baharvand
Hossein Baharvand
Islet transplantation has been hampered by loss of function due to poor revascularization. We hypothesize that co-transplantation of islets with human embryonic stem cell-derived mesenchymal stromal cells that conditionally overexpress VEGF (hESC-MSC:VEGF) may augment islet revascularization and reduce the minimal islet mass required to reverse diabetes in mice. HESC-MSCs were transduced by recombinant lentiviruses that allowed conditional (Dox-regulated) overexpression of VEGF. HESC-MSC:VEGF were characterized by tube formation assay. After co-transplantation of hESC-MSC:VEGF with murine islets in collagen-fibrin hydrogel in the omental pouch of diabetic nude mice, we measured blood glucose, body weight, glucose tolerance and serum C-peptide. As control, islets were transplanted alone or with non-transduced hESC-MSCs. Next, we compared functional parameters of 400 islets alone versus 200 islets co-transplanted with hESC-MSC:VEGF. As control, 200 islets were transplanted alone. Metabolic function of islets transplanted with hESC-MSC:VEGF significantly improved, accompanied by superior graft revascularization, compared with control groups. Transplantation of 200 islets with hESC-MSC:VEGF showed superior function over 400 islets alone. We conclude that co-transplantation of islets with VEGF-expressing hESC-MSCs allowed for at least a 50% reduction in minimal islet mass required to reverse diabetes in mice. This approach may contribute to alleviate the need for multiple donor organs per patient.

3 September 2018 in Immunopharmacology and Immunotoxicology
Verified
Journal Article
Closed access
RBRasoul Baharlou
Rasoul Baharlou
NTNader Tajik
Nader Tajik
MBMahdi Behdani
Mahdi Behdani
MSMohammad Ali Shokrgozar
Mohammad Ali Shokrgozar
VTVajiheh Tavana
Vajiheh Tavana
MHMahdi Habibi-Anbouhi
Mahdi Habibi-Anbouhi
Objectives: Angiogenesis targeting is an attractive approach for cancer treatment. Delta-like ligand 4 (DLL4) plays a pivotal role in neovascular development and its inhibitors have recently entered clinical trials for solid tumors. The aim of this study was to evaluate the possibilities of using anti-DLL4 antibody fragment as an angiogenesis maturation inhibitor. Materials and methods: In this study, a DLL4-specific Nanobody, named 3Nb3, was selected and assessed by western blotting and internalization assays. Functional assessments included MTT, apoptosis, and chicken chorioallantoic membrane (CAM) assays. Results: Based on the results, 3Nb3 specifically binds to DLL4 and internalizes into MKN cell. Furthermore, 3Nb3 significantly inhibited the proliferation of cells and also neovascularization in the CAM. Conclusions: These data demonstrated the potential of Nanobody for application in targeting DLL4. Our findings may provide a basis for the development of novel therapeutic techniques to inhibit growth and neovascularization of tumors.